| Literature DB >> 21389779 |
Abstract
The partial efficacy of the recent HIV-1 vaccine trial in Thailand has rejuvenated the HIV vaccine field. There are now clear opportunities to dissect the potential correlates of protection against HIV-1. Comparisons of three major HIV-1 vaccine strategies used in human efficacy trials to date highlight a possible role for antibody-dependent cellular cytotoxicty (ADCC), rather than cytotoxic T lymphocyte or neutralizing antibody responses, in protective immunity. This review explores the HIV vaccine efficacy trials performed to date and the potential role for ADCC antibodies in assisting protective immunity.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21389779 DOI： 10.4161/hv.7.4.14123
Source DB: PubMed Journal: Hum Vaccin ISSN： 1554-8600